TREM1 and hepatocellular carcinoma: Considering that CD8+ T cells play a critical role in anti-PD-L1 drug therapy, this result suggests that TREM1+ TAMs can be a potential target in anti-PD-L1-mediated immunotherapy in HCC [115,116,117].